Michelle Luo

Michelle Luo

Auto-generated profile, based on publicly available information

Michelle Luo

Takeda Pharmaceuticals U.S.A., Inc., Deerfield, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Open access
GMGerassimos J Mantzaris
Gerassimos J Mantzaris
BBBrian Bressler
Brian Bressler
SAShashi Adsul
Shashi Adsul
MLMichelle Luo
Michelle Luo
CCChris Colby
Chris Colby
AYAndres J Yarur
Andres J Yarur
Objectives: This study compared the real-world effectiveness and safety of α4β7-integrin inhibitor vedolizumab and anti-tumor necrosis factor alpha (anti-TNFα) inhibitor infliximab in biologic-naive patients with Crohn’s disease (CD). Methods: EVOLVE was a retrospective, multicenter, medical chart review of biologic-naive adults with inflammatory bowel disease receiving vedolizumab or anti-TNFα treatment as first-line biologics in Canada, Greece, and the USA. Twelve-month outcomes were analyzed in vedolizumab- or infliximab-treated patients with moderate-to-severe CD (and subgroups with complicated and noncomplicated CD) including cumulative rates of clinical response, clinical remission, and mucosal healing, and incidence rates of serious adverse events (SAEs) and serious infections (SIs). Inverse probability weighting (IPW) was used to account for baseline differences between treatment groups. Results: Data were analyzed from 167 patients. In the IPW dataset (99 vedolizumab-treated and 63 infliximab-treated), adjusted 12-month clinical remission rates were 73.1% and 55.2%, respectively (P = 0.31). Overall, effectiveness rates were similar across treatment and complicated/noncomplicated disease subgroups. Adjusted 12-month incidence rates (first occurrence/1000 person-years) of SAEs for vedolizumab vs. infliximab: 43.6 vs. 200.9 [hazard ratio (HR) 0.36 (0.09–1.54)]; SIs: 10.8 vs. 96.0 [HR 0.08 (<0.01–2.64)]. AE incidence was significantly lower in vedolizumab- vs. infliximab-treated patients for complicated [131.6 vs. 732.2; HR 0.19 (0.05–0.65)] and noncomplicated [276.3 vs. 494.8; HR 0.59 (0.35–0.99)] disease subgroups. Conclusion: These real-world data on first-line biologics show no differences in 12-month effectiveness outcomes for vedolizumab- vs. infliximab-treated biologic-naive patients with CD. Vedolizumab may have a more favorable safety profile vs. infliximab in patients with complicated and noncomplicated disease.

1 February 2024 in Blood
Verified
Journal Article
Closed access
PDF file
JBJames R. Byrnes
James R. Byrnes
TLTaek K Lee
Taek K Lee
SSSherif Sharaby
Sherif Sharaby
HCHeather Campbell
Heather Campbell
DDDre’vOn A. Dobson
Dre’vOn A. Dobson
AWAlisa Wolberg
Alisa Wolberg
Transglutaminase factor XIII (FXIII) is essential for hemostasis, wound healing, and pregnancy maintenance. Plasma FXIII is composed of A and B subunit dimers synthesized in cells of hematopoietic origin and hepatocytes, respectively. The subunits associate tightly in circulation as FXIII-A2B2. FXIII-B2 stabilizes the (pro)active site-containing FXIII-A subunits. Interestingly, people with genetic FXIII-A deficiency have decreased FXIII-B2, and therapeutic infusion of recombinant FXIII-A2 (rFXIII-A2) increases FXIII-B2, suggesting FXIII-A regulates FXIII-B secretion, production, and/or clearance. We analyzed humans and mice with genetic FXIII-A deficiency and developed a mouse model of rFXIII-A2 infusion to define mechanisms mediating plasma FXIII-B levels. Like humans with FXIII-A deficiency, mice with genetic FXIII-A deficiency had reduced circulating FXIII-B2, and infusion of FXIII-A2 increased FXIII-B2. FXIII-A-deficient mice had normal hepatic function and did not store FXIII-B in liver, indicating FXIII-A does not mediate FXIII-B secretion. Transcriptional analysis and polysome profiling indicated similar F13b levels and ribosome occupancy in FXIII-A-sufficient and -deficient mice and in FXIII-A-deficient mice infused with rFXIII-A2, indicating FXIII-A does not induce de novo FXIII-B synthesis. Unexpectedly, pharmacokinetic/pharmacodynamic modeling of FXIII-B antigen after rFXIII-A2 infusion in humans and mice suggested FXIII-A2 slows FXIII-B2 loss from plasma. Accordingly, comparison of free FXIII-B2 vs FXIII-A2-complexed FXIII-B2 (FXIII-A2B2) infused into mice revealed faster clearance of free FXIII-B2. These data show FXIII-A2 prevents FXIII-B2 loss from circulation and establish the mechanism underlying FXIII-B2 behavior in FXIII-A deficiency and during rFXIII-A2 therapy. Our findings reveal a unique, reciprocal relationship between independently synthesized subunits that mediate an essential hemostatic protein in circulation. This trial was registered at www.ClinicalTrials.com as #NCT00978380.

27 November 2023 in Molecular Oncology
Verified
Journal Article
Open access
NCNayela N. Chowdhury
Nayela N. Chowdhury
YYYi Yang
Yi Yang
ADAnanya Dutta
Ananya Dutta
MLMichelle Luo
Michelle Luo
ZWZimu Wei
Zimu Wei
MFMatthew Flick
Matthew Flick
Pancreatic ductal adenocarcinoma (PDAC) is a highly fatal metastatic disease associated with robust activation of the coagulation and fibrinolytic systems. However, the potential contribution of the primary fibrinolytic protease plasminogen to PDAC disease progression has remained largely undefined. Mice bearing C57Bl/6‐derived KPC (KRasG12D, TRP53R172H) tumors displayed evidence of plasmin activity in the form of high plasmin–antiplasmin complexes and high plasmin generation potential relative to mice without tumors. Notably, plasminogen‐deficient mice (Plg‐) had significantly diminished KPC tumor growth in subcutaneous and orthotopic implantation models. Moreover, the metastatic potential of KPC cells was significantly diminished in Plg‐ mice, which was linked to reduced early adhesion and/or survival of KPC tumor cells. The reduction in primary orthotopic KPC tumor growth in Plg‐ mice was associated with increased apoptosis, reduced accumulation of pro‐tumor immune cells, and increased local proinflammatory cytokine production. Elimination of fibrin(ogen), the primary proteolytic target of plasmin, did not alter KPC primary tumor growth and resulted in only a modest reduction in metastatic potential. In contrast, deficiencies in the plasminogen receptors Plg‐RKT or S100A10 in tumor cells significantly reduced tumor growth. Plg‐RKT reduction in tumor cells, but not reduced S100A10, suppressed metastatic potential in a manner that mimicked plasminogen deficiency. Finally, tumor growth was also reduced in NSG mice subcutaneously or orthotopically implanted with patient‐derived PDAC tumor cells in which circulating plasminogen was pharmacologically reduced. Collectively, these studies suggest that plasminogen promotes PDAC tumor growth and metastatic potential, in part through engaging plasminogen receptors on tumor cells.

16 January 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
DFD Faleck
D Faleck
PSP Shashi
P Shashi
JMJ Meserve
J Meserve
MRM Rahal
M Rahal
SKS Kadire
S Kadire
PDP S Dulai
P S Dulai
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for ulcerative colitis (UC). Using a multicentre, US-based consortium of UC patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior UC-related hospitalisation within the previous year, disease extent, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the physician global assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of UC-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (Mayo endoscopic subscore of 0 or 1). Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported for VDZ compared with TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.73). Of 646 UC patients, 334 were included after matching (n = 167 VDZ,; 49% male; median age 36 years). After adjusting for concomitant steroid use, concomitant immunomodulator (azathioprine, 6-mercaptopurine, methotrexate) use, and number of prior TNF-antagonists used, VDZ-treated patients had statistically significant higher 12-month cumulative rates of clinical remission (54% vs. 37%; HR 1.54, 95% CI 1.08–2.18) and endoscopic healing (50% vs. 42%, HR 1.73, 95% CI 1.10–2.73). Cumulative 12-month rates for steroid-free remission were numerically higher for VDZ-treated patients, but not statistically significant (49% vs. 38%; HR 1.43, 95% CI 0.79–2.60), These findings were consistent when stratified by disease extent and prior TNF-antagonist exposure. After accounting for measurable disease and patient-specific characteristics that may impact biologic effectiveness, we observed that VDZ-treated UC patients had significantly higher 12-month cumulative rates of clinical remission and endoscopic healing, and numerically higher steroid-free remission rates, when compared with TNF-antagonist–treated patients. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals U.S.A., Inc.

16 January 2018 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
MBM Bohm
M Bohm
SSS V Sagi
S V Sagi
MFM Fischer
M Fischer
SKS Kadire
S Kadire
GTG Tran
G Tran
PDP S Dulai
P S Dulai
We aimed to compare the effectiveness of vedolizumab (VDZ) to tumour necrosis factor (TNF)-antagonist therapy for Crohn’s disease (CD). Using a multicentre, US-based consortium of CD patients treated with VDZ or TNF-antagonist therapy, we performed propensity score matching (1:1) accounting for age, sex, prior CD-related hospitalisation within the previous year, stricturing or penetrating disease complication history, prior bowel surgery, disease severity, steroid refractoriness or dependence, and prior TNF-antagonist failure. Treatment response was categorised using the Physician Global Assessment. Using Cox proportional hazard models, we compared cumulative rates of clinical remission (complete resolution of CD-related symptoms), steroid-free remission (on steroids at baseline, tapered off, no repeat steroid prescription for 4 weeks), and endoscopic healing (absence of ulcers or erosions). Hazard ratios (HR) and 95% confidence intervals (CI) are reported for VDZ vs. TNF-antagonist therapy. The propensity score model accurately predicted treatment status (area under curve 0.80). Of 1122 CD patients, 538 were included after matching (n = 269 VDZ; 44% male; median age 35 years). After adjusting for concomitant steroid or immunomodulator use, disease location (isolated small bowel, ileocolonic, isolated colonic), and number of prior TNF-antagonists used, VDZ-treated patients had numerically, but not statistically significant higher 12-month cumulative rates for clinical remission (38% vs. 34%; HR 1.27, 95% CI 0.91–1.78) and steroid-free remission (26% vs. 18%; HR 1.75, 95% CI 0.90–3.43). VDZ-treated patients had significant higher 12-month cumulative rates for endoscopic healing (50% vs. 41%; HR 1.67, 95% CI 1.13–2.47). Among patients with colonic involvement, VDZ-treated patients had significantly higher rates of clinical remission, steroid-free remission, and endoscopic healing (Table 1). Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. Vedolizumab vs. TNF-antagonist therapy in Crohn’s disease. Adjusted for concomitant steroid use, concomitant immunomodulator use, and number of prior TNF-antagonists used. After accounting for measurable disease- and patient-specific characteristics that may affect biological effectiveness, VDZ-treated CD patients had numerically higher 12-month cumulative rates of clinical remission, steroid-free remission, and endoscopic healing than TNF-antagonist-treated patients. CD patients with colonic involvement were significantly more likely to respond to VDZ than to TNF-antagonist therapy. Randomised controlled trial data are needed to confirm these findings. Statistical analyses were conducted at the University of California, San Diego. Research funding was provided in part by Takeda Pharmaceuticals.

26 April 2024 in Extracellular Vesicle
Verified
Journal Article
Open access
AMAmber Morey
Amber Morey
MNMartin Ng
Martin Ng
Michail SpanosMichail Spanos
Michail Spanos
PZPiyan Zhang
Piyan Zhang
TXTuoye Xu
Tuoye Xu
RARoger Alexander
Roger Alexander
Antibodies are critical tools for research into extracellular vesicles (EVs) and other extracellular nanoparticles (ENPs), where they can be used for their identification, characterization, and isolation. However, the lack of a centralized antibody platform where researchers can share validation results thus minimizing wasted personnel time and reagents, has been a significant obstacle. Moreover, because the performance of antibodies varies among assay types and conditions, detailed information on assay variables and protocols is also of value. To facilitate sharing of results on antibodies that are relevant to EV/ENP research, the EV Antibody Database has been developed by the investigators of the Extracellular RNA Communication Consortium (ERCC). Hosted by the ExRNA Portal (https://exrna.org/resources/evabdb/), this interactive database aggregates and shares results from antibodies that have been tested by research groups in the EV/ENP field. Currently, the EV Antibody Database includes modules for antibodies tested for western Blot, EV Flow Cytometry, and EV Sandwich Assays, and holds 110 records contributed by 6 laboratories from the ERCC. Detailed information on antibody sources, assay conditions, and results is provided, including negative results. We encourage ongoing expert input and community feedback to enhance the database's utility, making it a valuable resource for comprehensive validation data on antibodies and protocols in EV biology.